Kevin Tang, Director at Heron Therapeutics, holds 3.85M shares in Rain Oncology (Ticker: RAIN), holds 4.39M shares in TCR2 Therapeutics (Ticker: TCRR), holds 10.00K shares in Jounce Therapeutics (Ticker: JNCE). Most recently, Kevin Tang Sold ― shares of Rain Oncology on Dec 18, 2023 for an estimated value of 209.41K.
Kevin Tang latest transaction was an Informative Sell of $209.41K.
What was Kevin Tang's most profitable transaction?
Kevin Tang’s most profitable transaction was an Informative Buy of LJPC stock on September 26, 2014. The return on the trade was 228.40%.
What is Kevin Tang's role in Heron Therapeutics?
Kevin Tang's role in Heron Therapeutics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.